Current treatment of IgA nephropathy
Open Access
- 8 September 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Seminars in Immunopathology
- Vol. 43 (5), 717-728
- https://doi.org/10.1007/s00281-021-00888-3
Abstract
IgA nephropathy (IgAN) is the most common type of glomerulonephritis in Asia and the Western world. In most patients, it follows an asymptomatic to oligosymptomatic course and GFR loss, if any, is slow. The mainstay of therapy therefore is optimized supportive care, i.e., measures that lower blood pressure, reduce proteinuria, minimize lifestyle risk factors, and otherwise help to reduce non-specific insults to the kidneys. The value of immunosuppression has become controversial and if at all, systemic high-dose corticosteroid therapy should be considered for a few months taking into account patient characteristics that would caution against or preclude such therapy. In addition, adverse events related to corticosteroid therapy markedly increase as GFR declines. Beyond corticosteroids, there is little evidence that any additional immunosuppression is helpful, with the exception of mycophenolate mofetil in patients of Asian descent. A considerable number of clinical trials ranging from enteric coated budesonide to blockade of B-cell function to complement inhibitors are currently ongoing and will hopefully allow a more targeted therapy of high-risk patients with progressive IgAN in the future.Keywords
Funding Information
- Universitätsklinikum RWTH Aachen
This publication has 82 references indexed in Scilit:
- The Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy – A Randomized Cross-Over StudyPLOS ONE, 2013
- Implementation of proteomic biomarkers: making it workEuropean Journal of Clinical Investigation, 2012
- Overweight and obesity accelerate the progression of IgA nephropathy: prognostic utility of a combination of BMI and histopathological parametersClinical and Experimental Nephrology, 2012
- AKI Associated with Macroscopic Glomerular HematuriaClinical Journal of the American Society of Nephrology, 2012
- Addition of Atrasentan to Renin-Angiotensin System Blockade Reduces Albuminuria in Diabetic NephropathyJournal of the American Society of Nephrology, 2011
- Addition of Azathioprine to Corticosteroids Does Not Benefit Patients with IgA NephropathyJournal of the American Society of Nephrology, 2010
- Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathyNephrology Dialysis Transplantation, 2010
- Toll-Like Receptor 9 Affects Severity of IgA NephropathyJournal of the American Society of Nephrology, 2008
- Aberrant IgA1 Glycosylation Is Inherited in Familial and Sporadic IgA NephropathyJournal of the American Society of Nephrology, 2008
- Histologically advanced IgA nephropathy treated successfully with prednisolone and cyclophosphamideClinical and Experimental Nephrology, 2007